{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:56:48Z","timestamp":1771329408533,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11914-010-0016-1","type":"journal-article","created":{"date-parts":[[2010,3,31]],"date-time":"2010-03-31T00:58:18Z","timestamp":1269997098000},"page":"84-90","source":"Crossref","is-referenced-by-count":51,"title":["PPARs in Bone: The Role in Bone Cell Differentiation and Regulation of Energy Metabolism"],"prefix":"10.1007","volume":"8","author":[{"given":"Beata","family":"Lecka-Czernik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,1]]},"reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"\u2022 Lee NK, Sowa H, Hinoi E, et al.: Endocrine regulation of energy metabolism by the skeleton. Cell 2007, 130:456\u2013469. This study demonstrates for the first time that bone-derived osteocalcin hormone regulates energy metabolism.","journal-title":"Cell"},{"issue":"Suppl 1","key":"16_CR2","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/j.1749-6632.2009.05061.x","volume":"1173","author":"E Hinoi","year":"2009","unstructured":"Hinoi E, Gao N, Jung DY, et al.: An osteoblast-dependent mechanism contributes to the leptin regulation of insulin secretion. Ann N Y Acad Sci 2009, 1173(Suppl 1):E20\u2013E30.","journal-title":"Ann N Y Acad Sci"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1634\/stemcells.19-3-180","volume":"19","author":"P Bianco","year":"2001","unstructured":"Bianco P, Riminucci M, Gronthos S, Robey PG: Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001, 19:180\u2013192.","journal-title":"Stem Cells"},{"key":"16_CR4","doi-asserted-by":"crossref","unstructured":"Lecka-Czernik B, Suva LJ: Resolving the two \u201cbony\u201d faces of PPAR-gamma. PPAR Res 2006, 2006:27489.","DOI":"10.1155\/PPAR\/2006\/27489"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nm1025","volume":"10","author":"RM Evans","year":"2004","unstructured":"Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004, 10:355\u2013361.","journal-title":"Nat Med"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","volume":"1771","author":"V Zoete","year":"2007","unstructured":"Zoete V, Grosdidier A, Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 2007, 1771:915\u2013925.","journal-title":"Biochim Biophys Acta"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289\u2013312.","journal-title":"Annu Rev Biochem"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","volume":"1771","author":"S Heikkinen","year":"2007","unstructured":"Heikkinen S, Auwerx J, Argmann CA: PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007, 1771:999\u20131013.","journal-title":"Biochim Biophys Acta"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1101\/gad.953802","volume":"16","author":"D Ren","year":"2002","unstructured":"Ren D, Collingwood TN, Rebar EJ, et al.: PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002, 16:27\u201332.","journal-title":"Genes Dev"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7","volume":"74","author":"B Lecka-Czernik","year":"1999","unstructured":"Lecka-Czernik B, Gubrij I, Moerman EA, et al.: Inhibition of Osf2\/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 1999, 74:357\u2013371.","journal-title":"J Cell Biochem"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev.biochem.70.1.341","volume":"70","author":"TM Willson","year":"2001","unstructured":"Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001, 70:341\u2013367.","journal-title":"Annu Rev Biochem"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1210\/er.2003-0036","volume":"25","author":"C Knouff","year":"2004","unstructured":"Knouff C, Auwerx J: Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 2004, 25:899\u2013918.","journal-title":"Endocr Rev"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/endo.143.6.8834","volume":"143","author":"B Lecka-Czernik","year":"2002","unstructured":"Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376\u20132384.","journal-title":"Endocrinology"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","volume":"13","author":"Y Wan","year":"2007","unstructured":"Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13:1496\u20131503.","journal-title":"Nat Med"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","volume":"145","author":"SO Rzonca","year":"2004","unstructured":"Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401\u2013406.","journal-title":"Endocrinology"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1210\/en.2006-1587","volume":"148","author":"OP Lazarenko","year":"2007","unstructured":"\u2022 Lazarenko OP, Rzonca SO, Hogue WR, et al.: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669\u20132680. This article shows that aging is a confounding factor for rosiglitazone-induced bone loss in mice.","journal-title":"Endocrinology"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1172\/JCI200419900","volume":"113","author":"T Akune","year":"2004","unstructured":"Akune T, Ohba S, Kamekura S, et al.: PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846\u2013855.","journal-title":"J Clin Invest"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ncprheum0070","volume":"2","author":"CJ Rosen","year":"2006","unstructured":"Rosen CJ, Bouxsein ML: Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35\u201343.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1474-9728.2004.00127.x","volume":"3","author":"EJ Moerman","year":"2004","unstructured":"Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma\/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta\/BMP signaling pathways. Aging Cell 2004, 3:379\u2013389.","journal-title":"Aging Cell"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12033-007-0057-6","volume":"37","author":"G Spiteller","year":"2007","unstructured":"Spiteller G: The important role of lipid peroxidation processes in aging and age dependent diseases. Mol Biotechnol 2007, 37:5\u201312.","journal-title":"Mol Biotechnol"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S8756-3282(02)00805-0","volume":"31","author":"AC Maurin","year":"2002","unstructured":"Maurin AC, Chavassieux PM, Vericel E, Meunier PJ: Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone 2002, 31:260\u2013266.","journal-title":"Bone"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"81219","DOI":"10.1155\/2007\/81219","volume":"2007","author":"KR Shockley","year":"2007","unstructured":"\u2022 Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B: PPAR\u03b32 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Research 2007, 2007:81219. This article demonstrates that PPAR-\u03b32 plays a major role in regulation of MSC \"stemness\" phenotype.","journal-title":"PPAR Research"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF02405340","volume":"36","author":"P Minaire","year":"1984","unstructured":"Minaire P, Edouard C, Arlot M, Meunier PJ: Marrow changes in paraplegic patients. Calcif Tissue Int 1984, 36:338\u2013340.","journal-title":"Calcif Tissue Int"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1152\/japplphysiol.91530.2008","volume":"107","author":"G Trudel","year":"2009","unstructured":"Trudel G, Payne M, Madler B, et al.: Bone marrow fat accumulation after 60\u00a0days of bed rest persisted 1\u00a0year after activities were resumed along with hemopoietic stimulation: the Women International Space Simulation for Exploration study. J Appl Physiol 2009, 107:540\u2013548.","journal-title":"J Appl Physiol"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11914-005-0003-0","volume":"3","author":"LJ Suva","year":"2005","unstructured":"Suva LJ, Gaddy D, Perrien DS, et al.: Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep 2005, 3:46\u201351.","journal-title":"Curr Osteoporos Rep"},{"key":"16_CR26","doi-asserted-by":"crossref","first-page":"64807","DOI":"10.1155\/PPAR\/2006\/64807","volume":"2006","author":"PJ Marie","year":"2006","unstructured":"Marie PJ, Kaabeche K: PPAR gamma and control of bone mass in skeletal unloading. PPAR Res 2006, 2006:64807.","journal-title":"PPAR Res"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/sj.embor.7400254","volume":"5","author":"TA Cock","year":"2004","unstructured":"Cock TA, Back J, Elefteriou F, et al.: Enhanced bone formation in lipodystrophic PPARgamma(hyp\/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004, 5:1007\u20131012.","journal-title":"EMBO Rep"},{"key":"16_CR28","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","volume":"146","author":"AA Ali","year":"2005","unstructured":"Ali AA, Weinstein RS, Stewart SA, et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226\u20131235.","journal-title":"Endocrinology"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00223-004-0224-8","volume":"75","author":"V Sottile","year":"2004","unstructured":"Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75:329\u2013337.","journal-title":"Calcif Tissue Int"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"18767","DOI":"10.1074\/jbc.M109.000836","volume":"284","author":"UI Modder","year":"2009","unstructured":"Modder UI, Monroe DG, Fraser DG, et al.: Skeletal consequences of deletion of steroid receptor coactivator-2\/transcription intermediary factor-2. J Biol Chem 2009, 284:18767\u201318777.","journal-title":"J Biol Chem"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.21994","volume":"106","author":"KR Shockley","year":"2009","unstructured":"\u2022 Shockley KR, Lazarenko OP, Czernik PJ, et al.: PPAR\u03b32 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232\u2013246. This article provides an extensive analysis of the effect of rosiglitazone on gene expression in marrow MSCs.","journal-title":"J Cell Biochem"},{"key":"16_CR32","first-page":"1085","volume":"10","author":"B Lecka-Czernik","year":"2009","unstructured":"Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009, 10:1085\u20131090.","journal-title":"Curr Opin Investig Drugs"},{"key":"16_CR33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"\u2022 Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845\u2013851. This article provides a retrospective analysis of fracture risk and type of fractures among the ADOPT participants.","journal-title":"Diabetes Care"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"\u2022 Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32\u201339. This article provides a comprehensive review of available clinical trials in respect to the effect of TZDs on risk of fractures.","journal-title":"CMAJ"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","volume":"168","author":"C Meier","year":"2008","unstructured":"Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820\u2013825.","journal-title":"Arch Intern Med"},{"key":"16_CR36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","volume":"116","author":"P Lefebvre","year":"2006","unstructured":"Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571\u2013580.","journal-title":"J Clin Invest"},{"key":"16_CR37","first-page":"129","volume":"16","author":"J Remick","year":"2008","unstructured":"Remick J, Weintraub H, Setton R, et al.: Fibrate therapy: an update. Cardiol Rev 2008, 16:129\u2013141.","journal-title":"Fibrate therapy: an update. Cardiol Rev"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1472-8206.2007.00486.x","volume":"21","author":"C Giaginis","year":"2007","unstructured":"Giaginis C, Tsantili-Kakoulidou A, Theocharis S: Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007, 21:231\u2013244.","journal-title":"Fundam Clin Pharmacol"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S8756-3282(99)00238-0","volume":"26","author":"X Wu","year":"2000","unstructured":"Wu X, Peters JM, Gonzalez FJ, et al.: Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 2000, 26:21\u201326.","journal-title":"Bone"},{"key":"16_CR40","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bcp.2004.08.016","volume":"68","author":"Q Yang","year":"2004","unstructured":"Yang Q, Gonzalez FJ: Peroxisome proliferator-activated receptor alpha regulates B lymphocyte development via an indirect pathway in mice. Biochem Pharmacol 2004, 68:2143\u20132150.","journal-title":"Biochem Pharmacol"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00223-008-9175-9","volume":"83","author":"K Still","year":"2008","unstructured":"Still K, Grabowski P, Mackie I, et al.: The peroxisome proliferator activator receptor alpha\/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 2008, 83:285\u2013292.","journal-title":"Calcif Tissue Int"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2006.07.029","volume":"40","author":"BY Chan","year":"2007","unstructured":"Chan BY, Gartland A, Wilson PJ, et al.: PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007, 40:149\u2013159.","journal-title":"Bone"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6823-9-10","volume":"9","author":"U Syversen","year":"2009","unstructured":"Syversen U, Stunes AK, Gustafsson BI, et al.: Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009, 9:10.","journal-title":"BMC Endocr Disord"},{"key":"16_CR44","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1001\/jama.283.24.3205","volume":"283","author":"CR Meier","year":"2000","unstructured":"Meier CR, Schlienger RG, Kraenzlin ME, et al.: HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283:3205\u20133210.","journal-title":"JAMA"},{"key":"16_CR45","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","volume":"116","author":"GD Barish","year":"2006","unstructured":"Barish GD, Narkar VA, Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590\u2013597.","journal-title":"J Clin Invest"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","volume":"113","author":"YX Wang","year":"2003","unstructured":"Wang YX, Lee CH, Tiep S, et al.: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159\u2013170.","journal-title":"Cell"},{"key":"16_CR47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/jcb.20777","volume":"98","author":"JM Gimble","year":"2006","unstructured":"Gimble JM, Zvonic S, Floyd ZE, et al.: Playing with bone and fat. J Cell Biochem 2006, 98:251\u2013266.","journal-title":"J Cell Biochem"},{"key":"16_CR48","first-page":"139","volume":"12","author":"M Tavassoli","year":"1984","unstructured":"Tavassoli M: Marrow adipose cells and hemopoiesis: an interpretative review. Exp Hematol 1984, 12:139\u2013146.","journal-title":"Exp Hematol"},{"key":"16_CR49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature03398","volume":"434","author":"F Elefteriou","year":"2005","unstructured":"Elefteriou F, Ahn JD, Takeda S, et al.: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514\u2013520.","journal-title":"Nature"},{"key":"16_CR50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jcb.20890","volume":"99","author":"Y Shinoda","year":"2006","unstructured":"Shinoda Y, Yamaguchi M, Ogata N, et al.: Regulation of bone formation by adiponectin through autocrine\/paracrine and endocrine pathways. J Cell Biochem 2006, 99:196\u2013208.","journal-title":"J Cell Biochem"},{"key":"16_CR51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.exger.2007.03.003","volume":"42","author":"MJ Cartwright","year":"2007","unstructured":"Cartwright MJ, Tchkonia T, Kirkland JL: Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol 2007, 42:463\u2013471.","journal-title":"Exp Gerontol"},{"key":"16_CR52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.exger.2009.05.009","volume":"44","author":"M Gasparrini","year":"2009","unstructured":"Gasparrini M, Rivas D, Elbaz A, Duque G: Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL\/6\u00a0J mice. Exp Gerontol 2009, 44:613\u2013618.","journal-title":"Exp Gerontol"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-010-0016-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-010-0016-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-010-0016-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:33:45Z","timestamp":1559421225000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-010-0016-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,1]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11914-010-0016-1","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,1]]}}}